Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials.

Nelson M, Fisher M, Gonzalez-Garcia J, Rockstroh JK, Weinstein D, Valdez H, Mayer H, van der Ryst E, Goodrich JM, Dang N.

HIV Clin Trials. 2010 May-Jun;11(3):145-55. doi: 10.1310/hct1103-145.

PMID:
20736151
2.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

3.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

4.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

PMID:
21555822
5.

Maraviroc.

Carter NJ, Keating GM.

Drugs. 2007;67(15):2277-88; discussion 2289-90. Review.

PMID:
17927288
6.

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558-64. doi: 10.1097/QAI.0b013e3181ee3d82.

7.

Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.

Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S.

J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):167-73. doi: 10.1097/QAI.0b013e3182a03d95.

8.

Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.

Moreno S, González J, Lekander I, Martí B, Oyagüez I, Sánchez-de la Rosa R, Casado MA.

Clin Ther. 2010 Dec;32(13):2232-45. doi: 10.1016/S0149-2918(10)80026-8.

PMID:
21316539
9.

Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.

Furtado J, Madruga JV, Bicudo EL, da Eira M, Lopes MI, Netto EM, Santini-Oliveira M, Leite OH, Machado AA, Tupinambas U, de Andrade Neto JL, Lima MP, Pedro Rde J, Miranda AF, Lewi DS, Santos BR, Portsmouth S, Wajsbrot DB, Cassoli LM.

AIDS Res Hum Retroviruses. 2013 Sep;29(9):1203-10. doi: 10.1089/AID.2012.0330. Epub 2013 Jun 25.

PMID:
23731330
10.

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

Saag M, Goodrich J, Fätkenheuer G, Clotet B, Clumeck N, Sullivan J, Westby M, van der Ryst E, Mayer H; A4001029 Study Group.

J Infect Dis. 2009 Jun 1;199(11):1638-47. doi: 10.1086/598965.

11.

[Maraviroc efficacy in clinical studies on the development of the molecule].

Moreno S, Hernández B, Gutiérrez C, Delsol E.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:17-22. Review. Spanish.

PMID:
19133217
12.

Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.

Ndegwa S.

Issues Emerg Health Technol. 2007 Dec;(110):1-8.

PMID:
18080399
13.

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.

Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG.

AIDS Res Hum Retroviruses. 2015 May;31(5):475-8. doi: 10.1089/AID.2014.0223. Epub 2014 Dec 17.

14.

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.

Jiang X, Feyertag F, Meehan CJ, McCormack GP, Travers SA, Craig C, Westby M, Lewis M, Robertson DL.

J Virol. 2015 Nov;89(22):11457-72. doi: 10.1128/JVI.01384-15. Epub 2015 Sep 2.

15.

Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals.

Babiker ZO, Douthwaite ST, Collier LE, Pennell A, Uriel AJ, Wilkins E.

J Int Assoc Provid AIDS Care. 2013 Jan-Feb;12(1):12-4. doi: 10.1177/1545109712462454. Epub 2012 Oct 16.

PMID:
23076664
16.

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.

Perry CM.

Drugs. 2010 Jun 18;70(9):1189-213. doi: 10.2165/11203940-000000000-00000. Review.

PMID:
20518583
17.

Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.

Stepanyuk O, Chiang TS, Dever LL, Paez SL, Smith SM, Perez G, Eng RH.

AIDS. 2009 Sep 10;23(14):1911-3. doi: 10.1097/QAD.0b013e32832f3c65.

PMID:
19584703
18.

Maraviroc.

Fadel H, Temesgen Z.

Drugs Today (Barc). 2007 Nov;43(11):749-58. doi: 10.1358/dot.2007.43.11.1131763. Review.

PMID:
18174962
19.

Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.

Rossetti B, Bianco C, Bellazzi LI, Bruzzone B, Colao G, Corsi P, Monno L, Pagano G, Paolucci S, Punzi G, Setti M, Zazzi M, De Luca A.

AIDS Res Hum Retroviruses. 2014 Jan;30(1):17-24. doi: 10.1089/AID.2012.0235. Epub 2013 Sep 17.

20.

Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.

Bonjoch A, Pou C, Pérez-Álvarez N, Bellido R, Casadellà M, Puig J, Noguera-Julian M, Clotet B, Negredo E, Paredes R.

J Antimicrob Chemother. 2013 Jun;68(6):1382-7. doi: 10.1093/jac/dks539. Epub 2013 Jan 25.

Items per page

Supplemental Content

Write to the Help Desk